Abstract:Purpose/Objective(s): Discovery of genetic drivers of radioresistance is critical for developing novel therapeutic strategies to combine with radiotherapy of radioresistant PDAC. In this study, we used genome-wide RNA-seq to identify genes upregulated in generated radioresistant PDAC cell lines and discovered the Inhibitor of DNA Binding 1 (ID1) gene as a potential regulator of radioresistance in PDAC. Materials/Methods: Radioresistant clones of the PDAC cell lines MIA PaCa-2 and PANC-1 were generated by delivering daily ionizing irradiation (IR) (2 Gy/day) in vitro over two weeks (total 20 Gy) followed by standard clonogenic assays following one week from the end of IR. The generated RR and parental cell lines were submitted for RNA-seq analysis to identify differentially expressed genes. The Limma R package was used to calculate differential expression among genes. Log2 fold change values were calculated for each sample compared to the control. Genes with an absolute fold change > 1 were considered significant. RNA sequencing expression data from the Cancer Genome Atlas (TCGA) database was analyzed through the online databases GEPIA, cBioPortal, and the Human Protein Atlas. Results: Following exposure to two weeks of 2 Gy daily IR in vitro, the two PDAC cell lines showed significantly greater clonogenic cell survival than their parental cell lines, indicating enhanced RR in these cells. RNA-seq analysis comparing parental and RR cell lines found upregulated seven genes (TNS4, ZDHHC8P1, APLNR, AQP3, SPP1, ID1, ID2) and seven genes downregulated (PTX3, ITGB2, EPS8L1, ALDH1L2, KCNT2, ARHGAP9, IFI16) in both RR cell lines. Western blotting confirmed increased expression of the ID1 protein in the RR cell lines compared to their parental cell lines. We found that ID1 mRNA was significantly higher in PDAC tumors compared to matched normal and high ID1 expression correlated with significantly worse disease-free survival (DFS) in PDAC patients (HR = 2.2, log rank P = 0.009). ID1 mRNA expression was also strongly correlated in tumors with TP53 mutation, a known driver of radioresistance. Conclusion: Our analysis indicates a novel role of ID1 in PDAC radioresistance. ID1 expression is higher in tumor tissue compared to normal, and high expression correlates with both worse DFS and association with the TP53 mutation, suggesting that targeting ID1 prior to IR is an attractive strategy for overcoming radioresistance in PDAC.

Sirna-Mediated Knockdown of ID1 Disrupts Nanog- and Oct-4-mediated Cancer Stem Cell-Likeness and Resistance to Chemotherapy in Gastric Cancer Cells.

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

Downregulation of Microrna-17-5p Inhibits Drug Resistance of Gastric Cancer Cells Partially Through Targeting P21.

GLUT-1 Sirna Enhances Radiosensitization of Laryngeal Cancer Stem Cells Via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis in Vitro and in Vivo.

Inhibitor of DNA-binding-1/inhibitor of Differentiation-1 (ID-1) is Implicated in Various Aspects of Gastric Cancer Cell Biology

Regulation of growth of gastric cancer cells and sensitivity to cisplatin by modulation of DNA binding inhibitor or differentiation protein expression

Involvement of Polo-like Kinase 1 (plk1) in Quiescence Regulation of Cancer Stem-Like Cells of the Gastric Cancer Cell Lines

Inhibitor of DNA binding 1 (Id1) mediates stemness of colorectal cancer cells through the Id1-c-Myc-PLAC8 axis via the Wnt/β-catenin and Shh signaling pathways.

Inhibitor Of Dna Binding1 (Id1) Mediates Stemness Of Colorectal Cancer Cells Through The Id1-C-Myc-Plac8 Axis Via The Wnt/Beta-Catenin And Shh Signaling Pathways

Silencing of RegIV by shRNA causes the loss of stemness properties of cancer stem cells in MKN45 gastric cancer cells.

ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways

RGS1 Serves As an Anti-Tumor Target to Inhibit Proliferation of NICN87-DR Cells and Tumor Growth in Gastric Cancer Mouse Model

Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq

Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.

Notch1 Silencing Inhibits Proliferation and Invasion in SGC-7901 Gastric Cancer Cells

Knockdown of TPT1-AS1 Inhibits Cell Proliferation, Cell Cycle G1/S Transition, and Epithelial–mesenchymal Transition in Gastric Cancer

Circ-0075305 hinders gastric cancer stem cells by indirectly disrupting TCF4–β-catenin complex and downregulation of SOX9

Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer

Knockdown of RhoGDI2 Represses Human Gastric Cancer Cell Proliferation, Invasion and Drug Resistance Via the Rac1/Pak1/LIMK1 Pathway.

Silencing Nanog expression inhibits MDA-MB-231 breast stem cancer cell growth in vitro and in vivo

Reduced Tumorigenicity and Drug Resistance Through the Downregulation of Octamer-Binding Protein 4 and Nanog Transcriptional Factor Expression in Human Breast Stem Cells